Clinical Trials
80 trialsEfficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Fujian Cancer Hospital
FEAD
Helse Stavanger HF
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study
Ningbo Medical Center Lihuili Hospital
2025-370
Henan Cancer Hospital
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
Henan Cancer Hospital
IMGeS
National Cancer Center, Korea
PrimPIPAC
Moscow Regional Oncological Dispensary
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
Fujian Cancer Hospital
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Taipei Veterans General Hospital, Taiwan
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Fujian Cancer Hospital
TENET
Tata Memorial Hospital
NEOPRIME
Vastra Gotaland Region
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Henan Cancer Hospital
NOGA
Tel-Aviv Sourasky Medical Center
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
Shandong Provincial Hospital
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
Henan Cancer Hospital
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Nizhny Novgorod Regional Clinical Oncology Center
NCCH2006/MK010 Trial (FORTUNE Trial)
National Cancer Center, Japan
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Henan Cancer Hospital
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
Anhui Provincial Hospital
KOV-02S
National Cancer Center, Korea
NICE-CC
Fujian Cancer Hospital
TARGET-01
Tata Memorial Hospital
LART
Azienda USL Reggio Emilia - IRCCS
DACT-GCT
National Cancer Institute, Slovakia
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Shandong Public Health Clinical Center
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
Shandong Public Health Clinical Center
OC-POP-PT
Tel-Aviv Sourasky Medical Center
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Henan Cancer Hospital
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Dulastin
National Cancer Center, Korea
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Zagazig University
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease
National Institute of CancerologÃa
AHTCRR-1
Nizhny Novgorod Regional Clinical Oncology Center
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
ACCESS-I
Instituto Nacional de Cancer, Brazil
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Shanghai Gynecologic Oncology Group
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Henan Cancer Hospital
Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients
National Cancer Center, Korea
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Henan Cancer Hospital
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Anhui Provincial Hospital
Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer
Shandong Provincial Hospital
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
Henan Cancer Hospital
SATELLITE
Queensland Centre for Gynaecological Cancer
Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT
Anhui Provincial Hospital
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Henan Cancer Hospital
Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer
Korea Institute of Oriental Medicine